These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36656467)

  • 1. Gene Modulation with CRISPR-based Tools in Human iPSC-Cardiomyocytes.
    Han JL; Entcheva E
    Stem Cell Rev Rep; 2023 May; 19(4):886-905. PubMed ID: 36656467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPRi/a Screening with Human iPSCs.
    Nishiga M; Qi LS; Wu JC
    Methods Mol Biol; 2021; 2320():261-281. PubMed ID: 34302664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Modulation of Chicken Genes In Vitro Using CRISPRa and CRISPRi Toolkit.
    Chapman B; Han JH; Lee HJ; Ruud I; Kim TH
    Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi.
    Bendixen L; Jensen TI; Bak RO
    Mol Ther; 2023 Jul; 31(7):1920-1937. PubMed ID: 36964659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes.
    Han JL; Heinson YW; Chua CJ; Liu W; Entcheva E
    Commun Biol; 2023 Dec; 6(1):1236. PubMed ID: 38062109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
    Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
    Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Developments in CRISPR/Cas-based Functional Genomics and their Implications for Research Using Zebrafish.
    Prykhozhij SV; Caceres L; Berman JN
    Curr Gene Ther; 2017; 17(4):286-300. PubMed ID: 29173171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of homozygous Na
    Maurer W; Hartmann N; Argyriou L; Sossalla S; Streckfuss-Bömeke K
    Stem Cell Res; 2022 Apr; 60():102677. PubMed ID: 35092938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
    Ben Jehuda R; Shemer Y; Binah O
    Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines.
    Sanjurjo-Soriano C; Erkilic N; Mamaeva D; Kalatzis V
    Methods Mol Biol; 2022; 2454():589-606. PubMed ID: 33755901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies.
    McTague A; Rossignoli G; Ferrini A; Barral S; Kurian MA
    Front Genome Ed; 2021; 3():630600. PubMed ID: 34713254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation.
    Dominguez AA; Lim WA; Qi LS
    Nat Rev Mol Cell Biol; 2016 Jan; 17(1):5-15. PubMed ID: 26670017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR technologies for stem cell engineering and regenerative medicine.
    Hsu MN; Chang YH; Truong VA; Lai PL; Nguyen TKN; Hu YC
    Biotechnol Adv; 2019 Dec; 37(8):107447. PubMed ID: 31513841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of CRISPR-Cas systems in neuroscience.
    Bonnerjee D; Bagh S
    Prog Mol Biol Transl Sci; 2021; 178():231-264. PubMed ID: 33685599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
    Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
    Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.